Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

Leukemia

Volumn 28, Issue 4, 2014, Pages 739-748

  Neri, L M ^a   Cani, A ^a   Martelli, A M ^b,c   Simioni, C ^a   Junghanss, C ^d   Tabellini, G ^e   Ricci, F ^f   Tazzari, P L ^f   Pagliaro, P ^f   McCubrey, J A ^g   Capitani, S ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Akt; B pre acute lymphoblastic leukemia; mTOR; RAD001; targeted therapy

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BECLIN 1; CASPASE 8; CASPASE 9; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCASPASE 9; PROTEIN KINASE B; TEMSIROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; B CELL LEUKEMIA; B LYMPHOCYTE; B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; AUTOPHAGY; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MULTIPROTEIN COMPLEXES; OXADIAZOLES; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84898460251     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.226     Document Type: Article

References (58)

1. Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ et al. Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol 2012; 43: 1347-1362.
2. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 2012; 26: 123-135.
3. De Braekeleer E, Basinko A, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C et al. Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer Genet Cytogenet 2010; 200: 8-15.
4. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603. (Pubitemid 36395654)
5. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064-1079.
6. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26: 1195-1202.
7. Silva A, Girio A, Cebola I, Santos CI, Antunes F, Barata JT. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011; 25: 960-967.
8. Fuka G, Kantner HP, Grausenburger R, Inthal A, Bauer E, Krapf G et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia 2012; 26: 927-933.
9. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006; 16: 78-84. (Pubitemid 43089616)
10. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537. (Pubitemid 40613318)
11. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101. (Pubitemid 40262113)
12. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24: 1686-1699.
13. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D et al. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012; 3: 371-394.
14. Zhao YM, Zhou Q, Xu Y, Lai XY, Huang H. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin 2008; 29: 481-488. (Pubitemid 351465508)
15. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400-1406. (Pubitemid 41129607)
16. Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100: 15113-15118. (Pubitemid 37518025)
17. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010; 10: 571-581.
18. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia 2008; 22: 2159-2168.
19. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341-347.
20. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165-5173. (Pubitemid 44453345)
21. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010; 116: 5983-5990.
22. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113: 1723-1729.
23. Zaliova M, Madzo J, Cario G, Trka J. Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing. Leukemia 2011; 25: 313-320.
24. Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012; 26: 91-100.
25. Schult C, Dahlhaus M, Ruck S, Sawitzky M, Amoroso F, Lange S et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B-and T-lymphoblastic cells. BMC Cancer 2010; 10: 560.
26. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013; 27: 650-660.
27. Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V et al. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia 2013; 27: 325-335.
28. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2012; 26: 271-279.
29. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012; 26: 2336-2342.
30. Evangelisti C, Ricci F, Tazzari P, Chiarini F, Battistelli M, Falcieri E et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 2011; 226: 822-831.
31. Zhang J, Xiao Y, Guo Y, Breslin P, Zhang S, Wei W et al. Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice. Leukemia 2011; 25: 1857-1868.
32. Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 2000; 7: 1263-1269. (Pubitemid 32042234)
33. Kim SI, Na HJ, Ding Y, Wang Z, Lee SJ, Choi ME. Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-beta1. J Biol Chem 2012; 287: 11677-11688.
34. Dall'Armi C, Devereaux KA, Di Paolo G. The role of lipids in the control of autophagy. Curr Biol 2013; 23: R33-R45.
35. Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res 2010; 16: 6029-6039.
36. Ren H, Chen M, Yue P, Tao H, Owonikoko TK, Ramalingam SS et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Lett 2012; 325: 139-146.
37. Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM et al. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012; 7: e31331.
38. Ewald F, Grabinski N, Grottke A, Windhorst S, Norz D, Carstensen L et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 2013; doi:10.1002/ijc.28214.
39. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
40. Tan S, Ng Y, James DE. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem J 2011; 435: 539-544.
41. Urashima M, Hoshi Y, Sugimoto Y, Kaihara C, Matsuzaki M, Chauhan D et al. A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. Leukemia 1996; 10: 1576-1583. (Pubitemid 26333811)
42. Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunol Res 2008; 42: 84-105.
43. Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell 2006; 9: 77-79. (Pubitemid 43202658)
44. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-2365. (Pubitemid 44497520)
45. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010; 27: 255-261.
46. Liu D, Huang Y, Chen B, Zeng J, Guo N, Zhang S et al. Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma. Cancer 2011; 117: 3763-3773.
47. Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y et al. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2010; 17: 2486-2493.
48. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T et al. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 59: 83-89.
49. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509-3512. (Pubitemid 46572543)
50. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011; 25: 781-791.
51. Levine B, Kroemer G. Autophagy in aging, disease and death: the true identity of a cell death impostor. Cell Death Differ 2009; 16: 1-2.
52. Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009; 5: 727-728.
53. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012; 11: 85.
54. Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A et al. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012; 72: 4483-4493.
55. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 2011; 96: 69-77.
56. Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia 2013; 27: 1479-1486.
57. Driscoll B, T'Ang A, Hu YH, Yan CL, Fu Y, Luo Y et al. Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb. J Biol Chem 1999; 274: 9463-9471.
58. Brantley Jr. MA. Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 2000; 60: 4320-4323. (Pubitemid 32103602)